Detailed characterization of tumor infiltrating lymphocytes in two distinct human solid malignancies show phenotypic similarities

Journal for ImmunoTherapy of Cancer

Volumn 2, Issue 1, 2014, Pages

  Kovacsovics Bankowski, Magdalena ^a   Chisholm, Lana ^a   Vercellini, Jonna ^a   Tucker, Christopher G ^a,b   Montler, Ryan ^b   Haley, Daniel ^a   Newell, Philippa ^a   Ma, Jun ^a   Tseng, Paul ^a   Wolf, Ronald ^a   Vetto, John T ^c   Hammill, Chet ^a   Hansen, Paul ^a   Weinberg, Andrew D ^a,b  

^a PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^b Agonox Inc   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Regulatory T cells; Tumor infiltrating lymphocytes

Indexed keywords

CD39 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 6; KI 67 ANTIGEN; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BIOPSY; BLOOD CELL; CARCINOSARCOMA; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; GENE FREQUENCY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; OVARY CANCER; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; UPREGULATION; VERY ELDERLY;

EID: 84977109113     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-014-0038-9     Document Type: Article

References (36)

1. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366(26):2443-2454. 10.1056/NEJMoa1200690, 22658127.
2. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366(26):2455-2465. 10.1056/NEJMoa1200694, 22658128.
3. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331(6024):1612-1616. 10.1126/science.1198443, 21436454.
4. Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010, 29(8):1093-1102. 10.1038/onc.2009.416, 19946335.
5. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman WH, Pages F, Galon J. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011, 71(4):1263-1271. 10.1158/0008-5472.CAN-10-2907, 21303976.
6. Kisielewicz A, Schaier M, Schmitt E, Hug F, Haensch GM, Meuer S, Zeier M, Sohn C, Steinborn A. A distinct subset of HLA-DR?+??regulatory T cells is involved in the induction of preterm labor during pregnancy and in the induction of organ rejection after transplantation. Clin Immunol 2010, 137(2):209-220. 10.1016/j.clim.2010.07.008, 20822960.
7. Schober L, Radnai D, Schmitt E, Mahnke K, Sohn C, Steinborn A. Term and preterm labor: decreased suppressive activity and changes in composition of the regulatory T-cell pool. Immunol Cell Biol 2012, 90(10):935-944. 10.1038/icb.2012.33, 22751216.
8. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 2006, 244(2):254-259. 10.1097/01.sla.0000217629.94941.cf, 16858188.
9. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004, 239(6):818-825. discussion 825?7, 10.1097/01.sla.0000128305.90650.71, 15166961.
10. Adam R, Wicherts DA, de Haas RJ, Ciacio O, Levi F, Paule B, Ducreux M, Azoulay D, Bismuth H, Castaing D. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?. J Clin Oncol 2009, 27(11):1829-1835. 10.1200/JCO.2008.19.9273, 19273699.
11. Wagner P, Koch M, Nummer D, Palm S, Galindo L, Autenrieth D, Rahbari N, Schmitz-Winnenthal FH, Schirrmacher V, Buchler MW, Beckhove P, Weitz J. Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer. Ann Surg Oncol 2008, 15(8):2310-2317. 10.1245/s10434-008-9971-5, 18521684.
12. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pages F, Galon J. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011, 29(6):610-618. 10.1200/JCO.2010.30.5425, 21245428.
13. Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol 2012, 124(2):192-198. 10.1016/j.ygyno.2011.09.039, 22040834.
14. Thompson JM, Gralow JR, Levy R, Miller RA. The optimal application of forward and ninety-degree light scatter in flow cytometry for the gating of mononuclear cells. Cytometry 1985, 6(5):401-406. 10.1002/cyto.990060503, 3899551.
15. Jenabian MA, Seddiki N, Yatim A, Carriere M, Hulin A, Younas M, Kok E, Ghadimi A, Routy JP, Tremblay A, Sevigny J, Lelievre JD, Levy Y: Regulatory T cells negatively affect IL-2 production of effector T cells through CD39/adenosine pathway in HIV infection. PLoS Pathog 2013, 9(4):e1003319..
16. Mandapathil M, Lang S, Gorelik E, Whiteside TL. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clin Cancer Res 2009, 15(20):6348-6357. 10.1158/1078-0432.CCR-09-1143, 19825957.
17. Zabransky DJ, Nirschl CJ, Durham NM, Park BV, Ceccato CM, Bruno TC, Tam AJ, Getnet D, Drake CG: Phenotypic and functional properties of Helios?+?regulatory T cells. PLoS One 2012, 7(3):e34547..
18. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995, 182:459-466. 10.1084/jem.182.2.459, 7543139.
19. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A, Fazekas de St Groth B. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006, 203(7):1693-1700. 10.1084/jem.20060468, 16818676.
20. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006, 203(7):1701-1711. 10.1084/jem.20060772, 16818678.
21. Jie HB, Gildener-Leapman N, Li J, Srivastava RM, Gibson SP, Whiteside TL, Ferris RL. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer 2013, 109(10):2629-2635. 10.1038/bjc.2013.645, 24169351.
22. Schuler PJ, Schilling B, Harasymczuk M, Hoffmann TK, Johnson J, Lang S, Whiteside TL. Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients. Eur J Immunol 2012, 42(7):1876-1885. 10.1002/eji.201142347, 22585562.
23. Camus M, Tosolini M, Mlecnik B, Pages F, Kirilovsky A, Berger A, Costes A, Bindea G, Charoentong P, Bruneval P, Trajanoski Z, Fridman WH, Galon J. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 2009, 69(6):2685-2693. 10.1158/0008-5472.CAN-08-2654, 19258510.
24. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348(3):203-213. 10.1056/NEJMoa020177, 12529460.
25. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, Murali-Krishna K, Mahar PL, Edupuganti S, Lalor S, Germon S, Del Rio C, Mulligan MJ, Staprans SI, Altman JD, Feinberg MB, Ahmed R. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008, 28(5):710-722. 10.1016/j.immuni.2008.02.020, 18468462.
26. Hagemann AR, Cadungog M, Hagemann IS, Hammond R, Adams SF, Chu CS, Rubin SC, Zhang L, Addya K, Birrer MJ, Gimotty PA, Coukos G. Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma. Cancer Biol Ther 2011, 12(4):367-377. 10.4161/cbt.12.4.16908, 21785280.
27. Pedroza-Gonzalez A, Verhoef C, Ijzermans JN, Peppelenbosch MP, Kwekkeboom J, Verheij J, Janssen HL, Sprengers D. Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology 2013, 57(1):183-194. 10.1002/hep.26013, 22911397.
28. Ma C, Dong X. Colorectal cancer-derived Foxp3(+) IL-17(+) T cells suppress tumour-specific CD8+ T cells. Scand J Immunol 2011, 74(1):47-51. 10.1111/j.1365-3083.2011.02539.x, 21352252.
29. Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology 2013, 138(2):105-115. 10.1111/imm.12036, 23216602.
30. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009, 114(8):1537-1544. 10.1182/blood-2008-12-195792, 19423728.
31. Anderson AC. Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol 2012, 24(2):213-216. 10.1016/j.coi.2011.12.005, 22226204.
32. Fisher DT, Appenheimer MM, Evans SS. The two faces of IL-6 in the tumor microenvironment. Semin Immunol 2014, 26(1):38-47. 10.1016/j.smim.2014.01.008, 24602448.
33. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007, 7(1):41-51. 10.1038/nri1995, 17186030.
34. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009, 9(11):798-809. 10.1038/nrc2734, 19851315.
35. Roederer M. Spectral compensation for flow cytometry: visualization artifacts, limitations, and caveats. Cytometry 2001, 45(3):194-205. 10.1002/1097-0320(20011101)45:3<194::AID-CYTO1163>3.0.CO;2-C, 11746088.
36. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. Cd4(+)cd25(high) regulatory cells in human peripheral blood. J Immunol 2001, 167(3):1245-1253. 10.4049/jimmunol.167.3.1245, 11466340.